Neoadjuvant chemotherapy of breast cancer: Tumor markers as predictors of pathologic response, recurrence, and survival

Breast Journal

Volumn 16, Issue 4, 2010, Pages 362-368

  Precht, Lisa M ^a   Lowe, Kimberly A ^b   Atwood, Mary ^a   Beatty, J David ^a  

^a SWEDISH MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Pathologic response; Recurrence; Survival; Tumor markers

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; RECURRENCE RISK; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 77956861823     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2010.00935.x     Document Type: Article

References (17)

1. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493
2. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project B-27. J Clin Oncol 2003;21:4165-4174
3. Abrial SC, Penault-Llorca F, Delva R, et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 2005;94:255-263
4. Chollet P, Amat S, Cure H, et al. Prognostic significance of complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002;86:1041-1046 (Pubitemid 34441058)
5. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685
6. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-2334
7. Rouzier R, Perou C, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685
8. Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004;40:205-211
9. Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004;10:6622-6628
10. Burcombe RJ, Makris A, Richman PI, et al. Evaluation of ER, PR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005;92:147-155
11. Tiezzi DG, Andrade JM, Ribeiro-Silva A, et al. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer 2007;7:36.
12. Bozzetti C, Musolino A, Camisa R, et al. Evaluation of HER2 / Neu amplification and other biological markers as predictors of response to neoadjuvant chemotherapy in primary breast cancer. Am J Clin Oncol 2006;29:171-177
13. Zhang F, Yang Y, Smith T, et al. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 2003;97:1758-1765
14. Beatty JD, Precht LM, Lowe K, Atwood M. Axillaryconserving surgery is facilitated by neoadjuvant chemotherapy of breast cancer. Am J Surg 2009;197:637-641 [Epub ahead of print]
15. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874
16. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423
17. Goldhirsch A, Glick JH, Gelber RD, et al. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Clin Oncol 2001;19:3817-3827